This article is written for general informational purposes and is not medical advice. By Sanjeevan’s own account, RP has no cure; the program is described as helping manage the condition and, in many reported cases, improve vision — not reverse the underlying genetic degeneration. Always consult a qualified ophthalmologist or retina specialist before starting any treatment.
For most people living with Retinitis Pigmentosa, the story starts quietly. Trouble seeing in a dim restaurant. Missing a step in low light. A blind spot at the edge of vision that’s easy to dismiss — until an eye exam turns it into a diagnosis. RP is a genetic disorder in which the retina’s rods and cones — the cells responsible for light and color detection — gradually break down. It typically begins with night blindness and narrowing peripheral vision, and in some patients eventually affects central and color vision as well. Progression varies widely from person to person.
Uttam was 32 when he was diagnosed. Like many patients, his first stop wasn’t a cure — it was a string of consultations that didn’t lead anywhere. “I visited many hospitals for my condition but did not find any solution,” he said. “I even went to Delhi but it didn’t work out.” It was only after finding Sanjeevan for Perfect Eyesight online that he began an active treatment plan — traveling from Panvel to their Bombay center to start.
Why integrative treatment, not just monitoring
Standard ophthalmology for RP centers on genetic counseling, low-vision rehabilitation, and — for a small subset of patients with specific known gene mutations — emerging gene therapies. For many patients, that leaves a wide gap between diagnosis and anything actively being done. Sanjeevan positions its RP program to sit in that gap. Their approach is integrative rather than purely pharmaceutical or surgical, combining several non-surgical modalities:
- Vision therapy — structured exercises aimed at improving visual function
- Electro-acupuncture and micro-acupuncture — targeted stimulation intended to support blood flow and retinal health
- Micro-current stimulation — low-level electrical currents applied to stimulate retinal cell activity
- Nutritional supplementation — targeted supplements to support retinal tissue
- Molecular Hydrogen Therapy — newer additions aimed at reducing oxidative stress, which is one contributor to photoreceptor breakdown
Sanjeevan’s own FAQ acknowledges this reality plainly: there is no cure for RP. What they describe offering instead is active management — an attempt to slow progression and support remaining vision, layered on top of proper diagnosis and monitoring.
Month 1: Diagnosis and baseline testing
Treatment begins with a full diagnostic workup: visual acuity testing, Optical Coherence Tomography (OCT) to image the retina in detail, and Perimetry to map the visual field and detect blind spots. Consultation is priced separately from testing (around ₹2,000 for consultation and ₹3,500 for perimetry and OCT, per the clinic’s published pricing), and the fuller treatment cost is quoted only after this baseline is complete. This baseline matters beyond pricing. Without documented starting numbers — visual field size, acuity, OCT imaging — there’s no reliable way to later separate genuine treatment response from the day-to-day fluctuation that’s common in RP, or from the placebo effect of simply feeling more hopeful during active treatment. Any patient considering this path, at Sanjeevan or elsewhere, should insist on this documentation up front.
Months 2–5: Active treatment phase
This is where the bulk of the program runs — regular sessions of electro-acupuncture, micro-current stimulation, and vision therapy, paired with ongoing nutritional support. For patients like Vadamakar, who was diagnosed at 36 after already losing significant vision, this phase is described as the point where reduced progression became noticeable: “She is glad to have found a treatment option for Retinitis Pigmentosa which has reduced the progression of her condition and helped improve her eye vision with therapy and treatments.” Sanjeevan recommends ongoing monitoring through this window — regular check-ins to track whether photophobia (light sensitivity), night vision, and peripheral field are stable, improving, or declining, and to adjust the plan accordingly.
Month 6: Re-evaluation
Toward the end of a typical six-month course, testing is repeated and compared against the original baseline. Sanjeevan reports that across their patient base, roughly 90% see some improvement in visual field on re-testing — a figure worth treating as a clinic-reported outcome rather than an independently verified clinical statistic, since it hasn’t gone through peer-reviewed publication. For Uttam, the six-month mark wasn’t framed as an endpoint but as evidence of direction: “So far I’ve seen progression in my vision,” he said of his ongoing care. That framing matters — Sanjeevan describes RP management as continuous rather than a one-time fix, with many patients continuing therapy well past the initial six months to maintain gains and keep monitoring the condition.
What this journey actually shows
Strip away the marketing language, and what Sanjeevan describes is a genuinely structured process: baseline testing, a multi-pronged non-surgical intervention, and re-testing against that baseline — not a vague promise. That structure is worth something on its own, regardless of which specific therapies are involved, because it gives patients and doctors something concrete to evaluate. If you’re a patient weighing this path, a few questions are worth asking before you start:
- Can I see my actual baseline numbers — visual field, OCT, acuity — not just a general description of my condition?
- What specifically will change between now and re-testing, and how will “improvement” be measured?
- Is my treating ophthalmologist aware I’m pursuing this, so both sides of my care stay coordinated?
RP is a hard diagnosis to sit with, precisely because mainstream medicine still has little to offer beyond monitoring for most patients. That’s exactly why documented, measurable evidence — not just optimism — should drive any decision about where to spend the next six months.
